KRAS G12D MUTATIONS
Clinical trials for KRAS G12D MUTATIONS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D MUTATIONS trials appear
Sign up with your email to follow new studies for KRAS G12D MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets tough pancreatic cancer mutation in 60-Patient trial
Disease control Recruiting nowThis study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). The goal is to see if the drug can shrink tumors or slow cancer growth, and to check for side effects. Participants must have a confi…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New targeted drug hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called GFH375 in about 400 adults with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. Participants must be 18-75…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC